discovered that patients with colorectal adenomas and cancers had higher anti-MUC1 antibody levels in their blood compared to healthy controls, suggesting that anti-MUC1 immune responses may contribute to tumor development inhibition (155). Here, MUC1 is linked to neoplasm.